alexa Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Vispo E, FernndezMontero JV, Labarga P, Barreiro P, Soriano V, Vispo E, FernndezMontero JV, Labarga P, Barreiro P, Soriano V

Abstract Share this page

Abstract Liver enzyme elevations (LEE) were investigated in 2717 episodes of initiation of antiretroviral therapy since January 2010 in 1982 HIV patients. Serum hepatitis C virus (HCV)-RNA was positive in 24\%. Any grade of LEE was recognized in 9\% of episodes, being 6\% in HCV-negative and 17\% in HCV-positive patients (P < 0.001). Grades 3-4 LEE only occurred in 0.4\% of patients. Overall, LEE were more frequent with ritonavir-boosted darunavir and atazanavir than with raltegravir and etravirine. This article was published in AIDS and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version